Liver Neoplasms

• FDA approval · 2018-07-26
  FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA approved a supplemental application for EOVIST (gadoxetate disodium) to expand/update its labeling for MRI imaging of focal liver le…

• FDA approval · 2013-10-16
  FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA has approved Bayer's supplemental application for Eovist (gadoxetate disodium), updating its labeling to expand its use as an MRI co…